Established in WA: 2004
Suite 5, 95 Hay Street, SUBIACO, 6008
0409 050 519
Dimerix is a clinical stage drug discovery and development company. The operational headquarters of the company are in Melbourne, where Dimerix’s lead clinical program is a Phase 2 study in Chronic Kidney Disease, DMX-200. This study has repurposing of existing molecules at its core, and upon successful results from this study, Dimerix Bioscience was established as a private company in 2004, based on technology developed at the University of Western Australia, known as Receptor-Heteromer Investigation Technology (HIT) Dimerix Bioscience underwent conversion to a public unlisted company in June 2014 and in July 2015 became a wholly owned subsidiary of Sun Biomedical Limited through a reverse takeover. Sun Biomedical’s name was changed to Dimerix Limited in November 2015.
Bio last updated 27 Apr 2017

Article Timeline

Access to our data for Dimerix is only available to paid subscribers with access.

The search engine is Western Australia's most accurate and comprehensive business listings and searchable database.

Dimerix is included in 1 list - Public Companies - Industrial.

For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.

To access ,

Dimerix (DXB)

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 29/06/18

1 year TSR5 year TSR
241stMGC Pharmaceuticals44%18%
702ndStrategic Elements-42%-6%
722 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

$20k Bought
$5k Bought
$50k Issued
Total value as at the date of the transaction
Source: Morningstar


178th↓Oakajee Corporation$158k
179th↓Strategic Elements$156k
182nd↓MGC Pharmaceuticals$120k
239 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer